CAT and metabolic dysfunction-associated steatotic liver disease: As depicted in Figure 1, we found decreased CAT levels in the +NAFLD patients compared to the −NAFLD group (340.48 ± 21.80 U/L vs. 471.99 ± 20.72 U/L; p < 0.001).